🕒 Last update: loading…

Stock Terns Pharmaceuticals, Inc. TERN

Terns Pharmaceuticals, Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ✅ Price trend passed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2021 → 2022: 43.99%

Price change 2022 → 2023: -36.25%

Price change 2023 → 2024: -14.64%

Price change 2024 → 2025: 629.24%

Price change 2025 → 2026: 31.06%

Price change 2026 (year to date): 32.01%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.00

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -51.41

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 0.00% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 05/02/2021
ISIN code
US8808811074
Workforce
59
full-time employees
Chief executive
Amy L. Burroughs

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Terns Pharmaceuticals, Inc.

Is Terns Pharmaceuticals, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US8808811074).

How many employees does Terns Pharmaceuticals, Inc. have?

59 full-time employees according to the latest published profile.

Who runs Terns Pharmaceuticals, Inc.?

Amy L. Burroughs is the company's chief executive.